Literature DB >> 6176703

Characterization of the antiviral activity produced during Trypanosoma cruzi infection and protective effects of exogenous interferon against experimental Chagas' disease.

F Kierszenbaum, G Sonnenfeld.   

Abstract

Mice infected with Trypanosoma cruzi have been shown to develop an antiviral activity in their sera as early as 24 hr postinfection. This activity was characterized in this work as alpha/beta interferon by the following criteria: resistance to pH 2 treatment, sensitivity to incubation at 56 C, or to trypsin treatment, or to actinomycin D treatment, and inactivation by antibody specific for alpha/beta interferon produced in L cells. Mice receiving exogenous alpha/beta interferon in seven daily doses starting on the day of infection with T. cruzi displayed an enhanced resistance evidenced by significantly decreased parasitemias with respect to those of infected animals receiving a mock preparation lacking interferon activity. Direct incubation of T. cruzi with interferon had no consequence on the motility, infectivity or virulence of the parasite. These results suggest a possible role for interferon in inducing enhancement of host resistance against T. cruzi infection.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6176703

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  9 in total

Review 1.  Pathogenesis of chagas' disease: parasite persistence and autoimmunity.

Authors:  Antonio R L Teixeira; Mariana M Hecht; Maria C Guimaro; Alessandro O Sousa; Nadjar Nitz
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

Review 2.  Animal models in interferon research: some current trends.

Authors:  H Schellekens
Journal:  Experientia       Date:  1989-06-15

3.  Type I interferons increase host susceptibility to Trypanosoma cruzi infection.

Authors:  Anne-Danielle C Chessler; Kacey L Caradonna; Akram Da'dara; Barbara A Burleigh
Journal:  Infect Immun       Date:  2011-03-14       Impact factor: 3.441

4.  Modulation of infection by gamma interferon treatment following trauma.

Authors:  M J Hershman; H C Polk; J D Pietsch; R E Shields; S R Wellhausen; G Sonnenfeld
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

5.  Treatment of murine macrophages with murine interferon-gamma and tumour necrosis factor-alpha enhances uptake and intracellular killing of Pseudomonas aeruginosa.

Authors:  S S Pierangeli; G Sonnenfeld
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

6.  Production of interferons during experimental African trypanosomiasis.

Authors:  G J Bancroft; C J Sutton; A G Morris; B A Askonas
Journal:  Clin Exp Immunol       Date:  1983-04       Impact factor: 4.330

7.  Involvement of beta interferon in enhancing inducible nitric oxide synthase production and antimicrobial activity of Burkholderia pseudomallei-infected macrophages.

Authors:  P Utaisincharoen; N Anuntagool; K Limposuwan; P Chaisuriya; S Sirisinha
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

8.  Gamma interferon suppresses acute and chronic Trypanosoma cruzi infection in cyclosporin-treated mice.

Authors:  R McCabe; S Meagher; B Mullins
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

9.  Enhancing effects of gamma interferon on phagocytic cell association with and killing of Trypanosoma cruzi.

Authors:  J J Wirth; F Kierszenbaum; G Sonnenfeld; A Zlotnik
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.